Evidence map›Paper›PMID 35334447›Full record

ArticleEuropean journal of medicinal chemistry2022

Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents.

Jimin Xu, Hyejin Kim, Jiabin Dong, Haiying Chen, Junhai Xu, Ruixia Ma, Mingxiang Zhou, Tianzhi Wang, Qiang Shen, Jia Zhou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jimin XuChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Hyejin KimDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, United States.
Jiabin DongDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, United States.
Haiying ChenChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Junhai XuDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, United States.
Ruixia MaDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, United States.
Mingxiang ZhouChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Tianzhi WangSealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, 77555, United States.
Qiang ShenDepartment of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, United States. Electronic address: qshen@lsuhsc.edu.
Jia ZhouChemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 77555, United States; Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, 77555, United States. Electronic address: jizhou@utmb.edu.
Louisiana State University Health Sciences Center New Orleans · USThe University of Texas Medical Branch at Galveston · US

Funding

Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152R01CA226001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, QIANG · 2018 to 2023
$2.2M
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast CancerR01CA231150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, QIANG · 2018 to 2023
$2.0M
NCI NIH HHS R01 CA226001NCI NIH HHS R01 CA231150
6 · The paper itself

Abstract

In our continued SAR study efforts, a series of O-alkylamino-tethered salicylamide derivatives with various amino acid linkers has been designed, synthesized, and biologically evaluated as potent anticancer agents. Five selected compounds with different representative chemical structures were found to show broad anti-proliferative activities, effective against all tested ER-positive breast cancer (BC) and triple-negative breast cancer (TNBC) cell lines with low micromolar IC

Indexed as

Antineoplastic AgentsTriple Negative Breast NeoplasmsAmino AcidsApoptosisCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureSalicylamidesStructure-Activity RelationshipAmino AcidsAntineoplastic AgentssalicylamideSalicylamidesAnticancer agentsBreast cancerDrug discoveryJMX0293Niclosamide derivativesSTAT3 inhibitors

Identifiers

PMID35334447
PMCPMC9040195
OpenAlexW4221060048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.